Pharmacologic Sleep Aids in the Intensive Care Unit: A Systematic Review
Journal of Intensive Care Medicine · 2025
DOI: 10.1177/08850666241255345 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Intensive Care Medicine, 2025. Verfasst von Gaurav Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary, Critical Care, and Sleep Medicine Section, Department of Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. Hauptthemen laut MEDLINE: Intensive Care Units, Melatonin, Sleep Aids, Pharmaceutical, Dexmedetomidine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 142 Literaturangaben.
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Patients in the intensive care unit (ICU) often experience poor sleep quality. Pharmacologic sleep aids are frequently used as primary or adjunctive therapy to improve sleep, although their benefits in the ICU remain uncertain. This review aims to provide a comprehensive assessment of the objective and subjective effects of medications used for sleep in the ICU, as well as their adverse effects.
Methods
PubMed, Web of Science, Scopus, Embase, and Cochrane Central Register of Controlled Trials were systematically searched from their inception until June 2023 for comparative studies assessing the effects of pharmacologic sleep aids on objective and subjective metrics of sleep.
Results
Thirty-four studies with 3498 participants were included. Medications evaluated were melatonin, ramelteon, suvorexant, propofol, and dexmedetomidine. The majority of studies were randomized controlled trials. Melatonin and dexmedetomidine were the best studied agents. Objective sleep metrics included polysomnography (PSG), electroencephalography (EEG), bispectral index, and actigraphy. Subjective outcome measures included patient questionnaires and nursing observations. Evidence for melatonin as a sleep aid in the ICU was mixed but largely not supportive for improving sleep. Evidence for ramelteon, suvorexant, and propofol was too limited to offer definitive recommendations. Both objective and subjective data supported dexmedetomidine as an effective sleep aid in the ICU, with PSG/EEG in 303 ICU patients demonstrating increased sleep duration and efficiency, decreased arousal index, decreased percentage of stage N1 sleep, and increased absolute and percentage of stage N2 sleep. Mild bradycardia and hypotension were reported as side effects of dexmedetomidine, whereas the other medications were reported to be safe. Several ongoing studies have not yet been published, mostly on melatonin and dexmedetomidine.
Conclusions
While definitive conclusions cannot be made for most medications, dexmedetomidine improved sleep quantity and quality in the ICU. These benefits need to be balanced with possible hemodynamic side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary, Critical Care, and Sleep Medicine Section, Department of Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University, Palo Alto, CA, USA.
ORCID-Profile: Gaurav Singh
Zitieren
APA
Singh, G., Nguyen, C., & Kuschner, W. (2025). Pharmacologic Sleep Aids in the Intensive Care Unit: A Systematic Review. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666241255345
Vancouver
Singh G, Nguyen C, Kuschner W. Pharmacologic Sleep Aids in the Intensive Care Unit: A Systematic Review. Journal of Intensive Care Medicine. 2025. doi:10.1177/08850666241255345
BibTeX
@article{Singh2025,
author = {Singh, Gaurav and Nguyen, Christopher and Kuschner, Ware},
title = {Pharmacologic Sleep Aids in the Intensive Care Unit: A Systematic Review},
journal = {Journal of Intensive Care Medicine},
year = {2025},
doi = {10.1177/08850666241255345}
}
EUVIMED